Non-exclusive Drug Discount Agreement for Raltegravir 400 mg
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Raltegravir 400 mg (ATC-Code nach WHO: J05AJ01)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum purchase; actual demand unknown and dependent on prescriptions, patient numbers, and pharmacy behavior.
Buyer may terminate the Open-House process early if exclusive rebate agreements are concluded, ending existing contract...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jun 30, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Supply of Raltegravir 400 mg tablets
- Participation in a non-exclusive drug discount agreement with AOK PLUS
Show full summary
Non-exclusive drug discount agreement for Raltegravir 400 mg (ATC J05AJ01) under an Open-House model. Any qualified pharmaceutical company can enter into a rebate contract with AOK PLUS. No guaranteed volumes, no exclusive rights, and no competitive award process. The agreement runs until June 30, 2028, with periodic submission deadlines. The contract value is not disclosed.
Risks
No minimum purchase; actual demand unknown and dependent on prescriptions, patient numbers, and pharmacy behavior.
Buyer may terminate the Open-House process early if exclusive rebate agreements are concluded, ending existing contract...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical enterprise as defined in §4 Abs. 18 AMG
- Must be established in Germany, EU, or EEA
Eligibility
- Submit self-declaration on absence of exclusion grounds (GWB §§123,124)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Drug Discount Agreement for Raltegravir 400 mg
Open to all interested pharmaceutical companies meeting participation requirements. The contract is a rebate agreement under §130a Abs. 8 SGB V. No minimum order quantity; volume depends on prescriptions and demand.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Raltegravir 400 mg (ATC-Code nach WHO: J05AJ01)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 07 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 238743-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum purchase; actual demand unknown and dependent on prescriptions, patient numbers, and pharmacy behavior.
Buyer may terminate the Open-House process early if exclusive rebate agreements are concluded, ending existing contract...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications